Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Savara Inc
(NQ:
SVRA
)
4.490
-0.150 (-3.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Savara Inc
< Previous
1
2
3
Next >
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
September 08, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
September 06, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Savara Inc.
Via
Business Wire
Savara Inc. (NASDAQ: SVRA) Making Surprising Moves in Monday Session
February 26, 2024
Via
Investor Brand Network
Savara Inc. (NASDAQ: SVRA) is a Stock Spotlight on 11/16
November 16, 2023
Via
Investor Brand Network
Savara Announces New Employment Inducement Grant
August 16, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
August 15, 2024
From
Savara Inc.
Via
Business Wire
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Savara Inc.
Via
Business Wire
Savara Inc. (NASDAQ: SVRA) is a Stock Spotlight on 11/6
November 06, 2023
Via
Investor Brand Network
Savara Inc. (NASDAQ: SVRA) is a Stock Spotlight on 10/25
October 25, 2023
Via
Investor Brand Network
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
June 28, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
June 26, 2024
From
Savara Inc.
Via
Business Wire
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
June 25, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Savara Inc.
Via
Business Wire
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
May 19, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
May 16, 2024
From
Savara Inc.
Via
Business Wire
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the Citizens JMP Life Sciences Conference
May 07, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
April 08, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
March 22, 2024
From
Savara Inc.
Via
Business Wire
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
March 07, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
February 02, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at Two Upcoming Healthcare Conferences
January 31, 2024
From
Savara Inc.
Via
Business Wire
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
December 21, 2023
From
Savara Inc.
Via
Business Wire
Savara Added to the NASDAQ Biotechnology Index
December 20, 2023
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
December 15, 2023
From
Savara Inc.
Via
Business Wire
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Savara Inc.
Via
Business Wire
Savara Reports Third Quarter Financial Results and Provides Business Update
November 09, 2023
From
Savara Inc.
Via
Business Wire
Savara to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
Savara Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.